| Factor Information | |
|---|---|
| Data ID | 2121 |
| Factor | PAPd (mm Hg) |
| Description | summarizes the hemodynamic effects of long-term continuous PGI2 administration. |
| Biomarker | NA |
| Classification | E9 (physiological factor - hemodynamic parameter) |
| Association | |
|---|---|
| Application | treatment and prognosis |
| Objective | In this study, we present the hemodynamic and clinical effects of long-term, continuous PGI2 administration in eight adult patients with CHD-PAH. |
| p Value | 0.002 |
| Conclusion | It summarizes the hemodynamic effects of long-term continuous PGI2 administration. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 584 |
| CHD Type | isolated CHD |
| CHD Subtype | ASD/TGA |
| Reference | |
|---|---|
| PMID | 23890862 |
| Year | 2013 |
| Title | Long-term effects of continuous prostacyclin therapy in adults with pulmonary hypertension associated with congenital heart disease |
| Sample | ||
|---|---|---|
| Population | Adults | |
| Source | Database | |
| Region | Chicago, United States | |
| Method | retrospectively reviewed | |
| Race | North America | |
| Disease History | N/A | |
| Treatment History | One patient had surgical correction of his congenital heart lesion at age 22 months. | |
| Group | after prostacyclin analogs (PGI2) therapy(Treatment) | Baseline(before PGI2 therapy)(Control) |
| Number | 8 | 8 |
| Age | 37 ± 10.5 years | 37 ± 10.5 years |
| Gender (Male: Female) | 2:6 | 2:6 |
| Marker Level | 39 ± 13 (mm Hg) | 50 ± 9 (mm Hg) |
